Results 11 to 20 of about 2,131 (185)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States [PDF]

The Journal of Headache and Pain, 2021
Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are limited. This
Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala, Alexander Mauskop   +9 more
doaj   +3 more sources

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study [PDF]

The Journal of Headache and Pain, 2020
Background We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO).
Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio, Ronghua Yang, Sait Ashina, Zaza Katsarava   +5 more
doaj   +2 more sources

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Journal of Pain Research, 2023
Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department ...
Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, Koga N   +8 more
doaj   +1 more source

Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries [PDF]

The Journal of Headache and Pain, 2018
Background Fremanezumab (TEV-48125) is a fully humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) that has shown positive results in the prevention of episodic migraine and chronic migraine.
Lena Ohlsson, Erik Kronvall, Jennifer Stratton, Lars Edvinsson   +3 more
doaj   +3 more sources

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

The Journal of Headache and Pain, 2021
Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine.
Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka, Hans-Christoph Diener   +8 more
doaj   +2 more sources

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy [PDF]

BMC Neurology
Background Chronic migraine (CM) is the most severe and burdensome subtype of migraine. Fremanezumab is a monoclonal antibody that targets the calcitonin gene-related peptide pathway as a migraine preventive therapy.
Sharon Wolters, Johannes A. Carpay, Marja H. Pronk, Karin W.M. Zuurbier, Maurice T. Driessen, Leonidas Lyras, Maarten J. Postma   +6 more
doaj   +2 more sources

Real-World effectiveness after initiating fremanezumab treatment in Brazilian patients with episodic and chronic migraine [PDF]

Headache Medicine
Background: Migraine is a debilitating condition, estimated to affect 30 million people in Brazil. Prevention may be considered for both episodic (EM) and chronic (CM) migraine and represents a real challenge in patient management.
Alexandre Kaup, João Jose Freitas de Carvalho   +1 more
doaj   +3 more sources

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response

Pain and Therapy
Introduction Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is indicated for preventive treatment of migraine in adults. Real-world evidence assessing the effect of fremanezumab on migraine-related medication use,
Dawn C. Buse, Lynda J. Krasenbaum, Michael J. Seminerio, Elizabeth R. Packnett, Karen Carr, Mario Ortega, Maurice T. Driessen   +6 more
doaj   +2 more sources

Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. [PDF]

, 2023
BACKGROUND The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine.
Poole, Anne Christine, Lyras, Leonidas,, Martins, Isabel Pavão, Ahn, Andrew H., Ramirez Campos, Verena, Mitsikostas, Dimos D, Pozo-Rosich, Patricia,, Sumelahti, Marja Liisa,, Nežádal, Tomáš,, Nežádal, Tomáš, Mitsikostas, Dimos D.,, Ahn, Andrew H.,, Sumelahti, Marja Liisa, Mitsikostas, Dimos D., Kokturk, Pinar,, Sahin, Gurdal,, Schankin, Christoph J.,, Tassorelli, Cristina, Schankin, Christoph J., Dorman, Paul J., Tassorelli, Cristina,, Dorman, Paul J.,, Dorman, Paul J, Amin, Faisal Mohammad,, Poole, Anne Christine,, Ahn, Andrew H, Sumelahti, Marja-Liisa, Ramirez Campos, Verena,, Kokturk, Pinar, Schankin, Christoph J, Lyras, Leonidas, Ashina, Messoud,, Pozo-Rosich, Patricia, Ashina, Messoud, Amin, Faisal Mohammad, Martins, Isabel Pavão,, Lund University., Sahin, Gurdal   +37 more
core   +3 more sources

Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

The Journal of Headache and Pain, 2020
Background The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who ...
Dawn C. Buse, Sanjay K. Gandhi, Joshua M. Cohen, Verena Ramirez-Campos, Blaine Cloud, Ronghua Yang, Robert P. Cowan   +6 more
doaj   +1 more source